Victoza Half-Life and Pharmacokinetics, Straight From the FDA Label

This is a reference page. Its job is to reproduce, accurately and with attribution, the pharmacokinetic statements in the FDA-approved United States prescribing information for Victoza, so somebody keeping a personal medication record can see where the numbers come from.

It is not medical advice. It has not been written or reviewed by a clinician, and it makes no recommendation about whether any medication is appropriate for anybody. It does not tell you how much to take, when to take it, or what to do about a dose you did not take. Those belong to your prescriber and pharmacist.

That last point matters more here than on the weekly pages, because a shorter half-life is exactly the circumstance in which people are most tempted to reason their own way to an answer.

All figures on this page come from one document: VICTOZA (liraglutide) injection — the United States Prescribing Information approved by the FDA, read on DailyMed accessed 1 September 2026. The pharmacokinetic statements sit in Section 12.3, Pharmacokinetics. The label records an Initial U.S. Approval of 2010.

Section 1 indicates Victoza as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Liraglutide is also marketed under a second brand name with a weight-management indication. The two labels are separate documents, and although they agree on half-life and bioavailability they do not state an identical time to peak — a difference covered on the companion page. Everything here is Victoza's own label.

Section 12.3 states a plasma half-life of approximately 13 hours after subcutaneous administration. Set against the rest of this class, that figure is the outlier: semaglutide's labeled half-life is approximately one week, tirzepatide's approximately five days, dulaglutide's approximately five days.

Thirteen hours is a different pharmacological regime, and the dosing schedule follows directly from it. Concentration falls substantially between one daily dose and the next rather than persisting at a plateau, which is why liraglutide is a daily medication and not a weekly one given more often.

It also changes what a gap in dosing means. For a weekly agent with a multi-day half-life, a missed dose sits on top of a large residual level. For a medication cleared this quickly, the picture is different. What follows from that for any individual is a question for a prescriber or pharmacist, and this page does not answer it.

The label states an absolute bioavailability of approximately 55% following subcutaneous administration.

That is a real difference from the weekly agents, whose labels give 80% for tirzepatide and 89% for semaglutide. Roughly half of an administered liraglutide dose reaches the systemic circulation, against the great majority for those others.

The practical significance is narrower than it might appear. Bioavailability matters when comparing routes of administration or reasoning about exposure across different products; it does not mean a medication is somehow working at half strength, because the approved strengths were established in trials conducted at those strengths. It is a descriptive pharmacokinetic property, quoted here because reference tables often report it inconsistently.

The label states that maximum concentration is reached 8 to 12 hours post dosing.

As on every page in this pillar, note the form: a window, not a point. A reference table that reports a single hour figure for liraglutide has selected a value from inside that range, and the selection is a modelling decision rather than a labeled fact.

This is worth flagging specifically for liraglutide because the two liraglutide products do not carry identical timing statements — one label gives a range and the other gives a specific hour. A table that merges them into one row will necessarily be quoting one label's figure under both products' names, and that is exactly the kind of quiet error this pillar exists to avoid.

Liraglutide is escalated gradually rather than started at a maintenance level, and the prescribing information describes that escalation in its dosage and administration section.

This page does not reproduce it — not the steps, not the intervals, not the conditions. A titration schedule is only meaningful attached to a specific person, and publishing one invites readers to follow it. Escalation is individualised for tolerability and for clinical circumstances no reference page can see.

The framing stays constant across this pillar: a stepwise schedule exists, it is defined in the label, and it is applied to you by your prescriber. What a record can do is capture accurately what was actually prescribed and actually taken.

GLP-1 Tracker records what you enter: the date of each dose you log, the injection site you noted, weight and BMI entries added over time, meals captured through the photo scan with calories, protein and fiber estimated, and notes about how a stretch of days went.

For a daily injectable, the thing worth having is continuity — a run of days rather than a set of isolated events. That is what makes a pattern visible, and it is what a clinician can actually use.

What the app does not do is decide anything. It does not evaluate whether your routine is working, it does not flag anything as clinically significant, and it does not generate schedules or tell you what to do about a gap.

GLP-1 Tracker includes an educational medication-level view that draws a curve from logged doses and a published half-life figure of the kind quoted on this page.

For a daily medication with a 13-hour half-life the curve looks quite different from the weekly agents' — more peaks and troughs, less of a smooth plateau — and that shape is genuinely instructive about why the dosing interval is what it is.

But it remains a teaching illustration built from population-level label figures rather than from you. It cannot account for your body weight, your kidney function, injection-site variation or ordinary biological variability. It is not a measurement, not a blood level, and not a clinical reading, and it should never influence a dose.